Sign In
Buy LGVN
$0.80
-0.0197 (-2.40%)
At Close: Jun 22, 2026
NEW YORK, Oct. 5, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12
Los Angeles, California--(Newsfile Corp. - October 4, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron In
Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment
08:43am, Monday, 04'th Oct 2021
Research and development of stem cell-based therapies, where a patient's own cells, or those from a donor, are used to fight injury and disease, is one of the fastest growing areas in the biotech spac
New York, New York--(Newsfile Corp. - October 1, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant a
New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and c
New York, New York--(Newsfile Corp. - October 1, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "
New York, New York--(Newsfile Corp. - September 29, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant
Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity
01:35pm, Wednesday, 29'th Sep 2021
Lomecel-B significantly decreased biomarker Tie-2 in Aging Frailty subjects at 270 days compared to placebo Significant, dose-dependent decrease in Tie-2 at Day 270
Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity
10:00am, Wednesday, 29'th Sep 2021
MIAMI, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and
New York, New York--(Newsfile Corp. - September 27, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no la
New York, New York--(Newsfile Corp. - September 25, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuan
New York, New York--(Newsfile Corp. - September 23, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant
New York, New York--(Newsfile Corp. - September 21, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no la
New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN)
-- Jorge Ruiz, M.D., Associate Director for Clinical Affairs, Geriatric Research at the Miami VA Healthcare System, will present Longeveron's Aging Frailty Phase 2b Trial Data
